

I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method for treating a person suffering from retinal edema or non-proliferative diabetic retinopathy which comprises, administering an effective amount of a ~~formulation free of classical preservatives and composition~~ comprising a glucocorticoid and anecortave acetate, wherein said composition is free of classical preservatives.

2. (cancel)

3. (new) The method of claim 1, wherein the glucocorticoid is selected from the group consisting of dexamethasone, fluoromethalone, medrysone, betamethasone, triamcinolone, triamcinolone acetonide, prednisone, prednisolone, hydrocortisone, rimexolone, and pharmaceutically acceptable salts thereof.

4. (new) The method of claim 1, wherein the glucocorticoid is selected from the group consisting of prednicarbate, deflazacort, halomethasone, tixocortol, prednylidene (21-diethylaminoacetate), prednival, paramethasone, methylprednisolone, meprednisone, mazipredone, isoflupredone, halopredone acetate, halcinonide, formocortal, flurandrenolide, fluprednisolone, fluprednidien acetate, fluperolone acetate, fluocortolone, fluocortin buytl, fluocinonide, fluocinolone acetonide, flunisolide, flumethasone, fludrocortisone, fluclorinide, enoxolone, difluprednate, diflucortolone, diflorasone diacetate, desoximetasone (desoxymethasone), desonide, descinolone, cortivazol, corticosterone, cortisone, cloprednol, clocortolone, clobetasone, clobetasol, chloroprednisone, cafestol, budesonide, beclomethasone, amcinonide, allopregnane acetonide, alclometasone, 21-acetoxypregnenolone, tralonide, diflorasone acetate, deacylcortivazol, RU-26988, budesonide, and deacylcortivazol oxetanone.

5. (new) The method of claim 3, wherein the glucocorticoid is triamcinolone acetonide.

6. (new) The method of claim 5, wherein the concentration of triamcinolone acetonide in the composition is from 0.4% to 4.0% w/v.

7. (new) The method of claim 2, wherein the glucocorticoid is rimexolone.
8. (new) The method of claim 7, wherein the concentration of rimexolone in the composition is from 0.1% to 4.0% w/v.
9. (new) The method of claim 2, wherein the glucocorticoid is prednisolone acetate.
10. (new) The method of claim 9, wherein the concentration of prednisolone acetate in the composition is from 0.1% to 2.0% w/v.
11. (new) The method of claim 2, wherein the glucocorticoid is fluoromethalone acetate.
12. (new) The method of claim 11, wherein the concentration of fluoromethalone acetate in the composition is from 0.1% to 1.0% w/v.
13. (new) The method of claim 6, wherein the concentration of anecortave acetate in the composition is from 0.1% to 6% w/v and the concentration of triamcinolone acetonide in the composition is from 0.5% to 2.0% w/v.
14. (new) The method of claim 13, wherein the concentration of anecortave acetate in the composition is from 1% to 3% w/v.
15. (new) The method of claim 14, wherein the concentration of anecortave acetate in the composition is 3% w/v.
16. (new) The method of claim 2, wherein the composition is delivered by a method selected from the group consisting of intravitreal injection, posterior juxtasccleral delivery, subconjunctival injection, and implanted device.
17. (new) The method of claim 16, wherein the composition is delivered by posterior juxtasccleral injection.
18. (new) The method of claim 16, wherein the composition is delivered via an

implanted device.